Nan Xu

Dr. Nan Xu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Viruses
Verified
Journal Article
Open access
PDF file
CLChunnan Liang
Chunnan Liang
CZChenyan Zhao
Chenyan Zhao
TLTianlong Liu
Tianlong Liu
LBLiu Bo
Liu Bo
ZLZhiguo Liu
Zhiguo Liu
YWYouchun Wang
Youchun Wang
Chronic hepatitis E virus (HEV) infection is frequently reported in immunocompromised patients, but has also been increasingly reported in non-immunocompromised individuals. We characterized the course of chronic HEV infection in immunocompetent rabbits. In two independent experiments, 40 specific-pathogen-free rabbits were infected with a rabbit HEV genotype 3 strain in serial diluted titers (108 to 104 copies/mL). Serum and fecal samples were collected weekly and were tested for HEV RNA, antigen, anti-HEV and liver enzymes. Rabbits that spontaneously cleared the infection before 10 weeks post-inoculation (wpi) were kept to the end of the study as recovery control. Liver tissues were collected from HEV-infected rabbits at 5, 10 and 26 wpi for histopathological analysis. Nineteen rabbits (47.5%) developed chronic HEV infection with persistent viraemia and fecal HEV shedding for >6 months. Seroconversion to anti-HEV was observed in 84.2% (16/19) of the chronically infected rabbits. Serum levels of aminotransferase were persistently elevated in most of the rabbits. Characterizations of chronic HEV infection in immunocompetent settings could be recapitulated in rabbits, which can serve as a valuable tool for future studies on pathogenesis.

25 January 2025 in Viruses
Verified
Journal Article
Open access
PDF file
NXNan Xu
Nan Xu
YSYanru Shen
Yanru Shen
WHWeijin Huang
Weijin Huang
Jianhui NieJianhui Nie
Jianhui Nie
Human immunodeficiency virus (HIV)-infected individuals have an increased risk of various infections due to their impaired host immune system, resulting in higher morbidity and mortality rates. These patients severely suffered during the COVID-19 epidemic, the influenza epidemic and the spread of monkeypox. Reducing serious infections is one of the most important measures to improve HIV-infected individuals’ quality and length of life. Based on the preparation processes and their antigenic properties, vaccines are divided into several types, including inactivated vaccines, attenuated live vaccines, recombinant protein vaccines, toxoid vaccines, polysaccharide vaccines, polysaccharide (protein) combined vaccines, nucleic acid vaccines, viral vector vaccines, etc. With the innovation of vaccine preparation technology in recent years and the acceleration of vaccine approval and market launch, more and more vaccine products suitable for HIV-infected individuals have become available. Because of their deficient immune systems, the type of vaccines and the schedule of vaccinations available to individuals living with HIV are sometimes different from those with healthy immune systems. This article reviewed the current status of vaccination in and shed light on the vaccination strategies for HIV-infected persons in terms of their safety and effectiveness.

25 May 2023
Verified
Book Chapter
Closed access
PDF file
YZYan Zhou
Yan Zhou
CZChenyan Zhao
Chenyan Zhao
YTYabin Tian
Yabin Tian
NXNan Xu
Nan Xu
YWYouchun Wang
Youchun Wang

4 November 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
NXNan Xu
Nan Xu
YLYu Liu
Yu Liu
CZChunhui Zhao
Chunhui Zhao
JHJinpan Hu
Jinpan Hu
LWLiangliang Wang
Liangliang Wang
Jianhui NieJianhui Nie
Jianhui Nie
Background/Objectives: The development of human papillomavirus (HPV) vaccines is increasingly trending toward multivalency, and accurate quantification of HPV virus-like particles (VLPs) is critical for vaccine quality control. All marketed products currently rely on ELISA-based antigen quantification, which is complex and time-consuming. In accordance with the 3Rs principles, in vitro potency testing is expected to progressively replace in vivo testing. Therefore, efficient and convenient antigen quantification methods for multivalent HPV vaccines are essential to improve testing efficiency. Methods: In this study, photosensitive substances were loaded into beads of different diameters using a swelling method, and carboxyl groups were introduced onto the bead surfaces. By coupling HPV monoclonal antibodies via carboxyl groups, the use of high-risk coupling reagents was avoided, and a one-step light-initiated chemiluminescence assay (LiCA) was established for the in vitro relative potency testing of HPV vaccines. Results: The LiCA method established using 200 nm carboxyl-coupled beads for the HPV16/18 bivalent vaccine exhibited excellent linear range, specificity, accuracy, and precision. The LiCA results were comparable to those of ELISA; moreover, compared with ELISA, LiCA showed a lower detection limit and a wider dynamic range for both HPV16 and HPV18 VLP antigens, and was more convenient and time-saving to operate. Conclusions: A one-step LiCA was established using carboxyl-coupled beads with optimized diameters, providing an efficient and convenient approach for the in vitro relative potency testing of multivalent HPV vaccines based on large-particle VLP systems, which contributes to improved vaccine quality control and testing efficiency.